Pegylated Liposomal Doxorubicin and Gemcitabine for Breast Cancer
Author Information
Author(s): Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D, Condemi G, Priolo D, Di Lullo L, Paglia A, Pisconti S, Scambia G, Ferrandina G
Primary Institution: University Hospital G Martino, Messina, Italy
Hypothesis
The study aimed to investigate the activity and safety of pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) as front-line therapy in chemotherapy-naïve recurrent/metastatic breast cancer patients.
Conclusion
The combination of PLD and GEM is effective and safe for treating chemotherapy-naïve recurrent/metastatic breast cancer patients, with a significant overall response rate and manageable toxicity.
Supporting Evidence
- The overall response rate was 39.1%, with 12.5% complete responses and 26.6% partial responses.
- Median time to progression was 11 months, and median overall survival was not reached.
- The clinical benefit rate was 85.9%, including stable disease.
Takeaway
This study tested a new medicine combination for breast cancer and found it works well and is safe for patients who haven't had chemotherapy before.
Methodology
This multicentre phase II study evaluated the efficacy and safety of PLD and GEM in chemotherapy-naïve recurrent/metastatic breast cancer patients.
Potential Biases
Potential biases may arise from the non-randomized nature of the study and the selection criteria for participants.
Limitations
The study's findings may be limited by the non-randomized design and the specific patient population studied.
Participant Demographics
Median age was 63 years, with 43.7% of patients aged 65 or older.
Statistical Information
P-Value
0.039
Confidence Interval
95% CI for overall response rate: 27.1, 50.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website